135 related articles for article (PubMed ID: 10647876)
21. Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia.
Martyré MC; Magdelenat H; Bryckaert MC; Laine-Bidron C; Calvo F
Br J Haematol; 1991 Jan; 77(1):80-6. PubMed ID: 1998600
[TBL] [Abstract][Full Text] [Related]
22. Aberrant expression of platelet-derived growth factor (PDGF) and PDGF receptor-alpha is associated with advanced bone marrow fibrosis in idiopathic myelofibrosis.
Bock O; Loch G; Büsche G; von Wasielewski R; Schlué J; Kreipe H
Haematologica; 2005 Jan; 90(1):133-4. PubMed ID: 15642683
[TBL] [Abstract][Full Text] [Related]
23. Carboxy-terminal fragment of osteogenic growth peptide in vitro increases bone marrow cell density in idiopathic myelofibrosis.
Fazzi R; Pacini S; Testi R; Azzarà A; Galimberti S; Testi C; Trombi L; Metelli MR; Petrini M
Br J Haematol; 2003 Apr; 121(1):76-85. PubMed ID: 12670334
[TBL] [Abstract][Full Text] [Related]
24. Idiopathic primary osteo-myelofibrosis: a clinico-pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact.
Thiele J; Kvasnicka HM; Werden C; Zankovich R; Diehl V; Fischer R
Leuk Lymphoma; 1996 Jul; 22(3-4):303-17. PubMed ID: 8819080
[TBL] [Abstract][Full Text] [Related]
25. Treatment of Myelofibrosis: A Moving Target.
Cerquozzi S; Farhadfar N; Tefferi A
Cancer J; 2016; 22(1):51-61. PubMed ID: 26841017
[TBL] [Abstract][Full Text] [Related]
26. [Use of interferon in the treatment of chronic myeloproliferative disorders].
Robak T
Acta Haematol Pol; 1992; 23(2 Suppl 1):30-7. PubMed ID: 1488870
[TBL] [Abstract][Full Text] [Related]
27. Idiopathic myelofibrosis without dacryocytes.
Chen GL; Liu E; Naidoo K; Popat U; Coetzer TL; Prchal JT
Haematologica; 2006 Jun; 91(6 Suppl):ECR29. PubMed ID: 16785132
[TBL] [Abstract][Full Text] [Related]
28. [New insight into pathogenesis of idiopathic myelofibrosis--review].
Xu ZQ; Sun XM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1330-4. PubMed ID: 18088495
[TBL] [Abstract][Full Text] [Related]
29. Relevance of bone marrow features in the differential diagnosis between essential thrombocythemia and early stage idiopathic myelofibrosis.
Thiele J; Kvasnicka HM; Zankovich R; Diehl V
Haematologica; 2000 Nov; 85(11):1126-34. PubMed ID: 11064463
[TBL] [Abstract][Full Text] [Related]
30. Reversal of myelofibrosis by hydroxyurea.
Löfvenberg E; Wahlin A; Roos G; Ost A
Eur J Haematol; 1990 Jan; 44(1):33-8. PubMed ID: 2307218
[TBL] [Abstract][Full Text] [Related]
31. Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy.
O'Neill C; Siddiqi I; Brynes RK; Vergara-Lluri M; Moschiano E; O'Connell C
Ann Hematol; 2016 Apr; 95(5):733-8. PubMed ID: 26961933
[TBL] [Abstract][Full Text] [Related]
32. Interferon-gamma in vivo reverses the increased platelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia.
Martyré MC; Magdelenat H; Calvo F
Br J Haematol; 1991 Mar; 77(3):431-5. PubMed ID: 1901495
[TBL] [Abstract][Full Text] [Related]
33. CD8
Yao Y; Li L; Yang SH; Gao CY; Liao LH; Xie YQ; Yin XY; Yang YQ; Fei YY; Lian ZX
J Autoimmun; 2018 May; 89():101-111. PubMed ID: 29307587
[TBL] [Abstract][Full Text] [Related]
34. [Improvement of bone marrow hematopoiesis in idiopathic myelofibrosis with prednisolone].
Tanosaki R; Uchida H; Masuda Y; Michikawa N; Ogawa T; Kubo A; Ikeda Y
Rinsho Ketsueki; 1992 Feb; 33(2):256-8. PubMed ID: 1635179
[TBL] [Abstract][Full Text] [Related]
35. Transplant decision-making strategies in the myeloproliferative disorders.
Fruchtman SM
Semin Hematol; 2003 Jan; 40(1 Suppl 1):30-3. PubMed ID: 12682880
[TBL] [Abstract][Full Text] [Related]
36. Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis.
Le Bousse-Kerdilès MC; Martyré MC
Ann Hematol; 1999 Oct; 78(10):437-44. PubMed ID: 10550553
[TBL] [Abstract][Full Text] [Related]
37. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy with recombinant human erythropoietin, interferon-alpha-2b and granulocyte-macrophage colony-stimulating factor in idiopathic myelofibrosis.
Bourantas KL; Tsiara S; Christou L; Repousis P; Konstantinidou P; Bai M; Seferiadis K
Acta Haematol; 1996; 96(2):79-82. PubMed ID: 8701705
[TBL] [Abstract][Full Text] [Related]
39. [A case of chronic neutrophilic leukemia accompanied with severe bone marrow fibrosis which was effectively treated by hydroxyurea].
Hirayama Y; Koda K; Matsumoto S; Takayanagi M; Ezoe A; Nobuoka A; Nakazawa O
Rinsho Ketsueki; 1994 Nov; 35(11):1329-34. PubMed ID: 7823400
[TBL] [Abstract][Full Text] [Related]
40. Comparative effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukemia.
Thiele J; Kvasnicka HM
Leuk Lymphoma; 2001; 42(5):855-62. PubMed ID: 11697640
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
